Galapagos to present GLPG0634 at ACR
16 Ottobre 2013 - 7:34AM
Galapagos NV (Euronext: GLPG) announced
today that the Company will present data on the pharmacodynamics and efficacy of
its selective JAK1 inhibitor GLPG0634 at the ACR (American College of
Rheumatology) which will take place from 25-30 October 2013 in San Diego, CA,
US. The abstracts are now available online on the ACR website.
Analysis of the JAK1 selectivity of GLPG0634 and its main metabolite in
different species, healthy volunteers and rheumatoid arthritis patients
Abstract # 478
Poster session - Sunday, October 27, 2013, 8.30 - 4.00 pm
An active metabolite contributes to the pharmacodynamics and efficacy of
GLPG0634, a selective JAK1 inhibitor
Abstract # 1795
Oral session - Monday, October 28, 2013, 4.30 - 6.00 pm
The JAK1-selective inhibitor GLPG0634 is safe and rapidly reduces disease
activity in patients with moderate to severe rheumatoid arthritis; results of a
4-week dose ranging study
Abstract # 2381
Poster session - Tuesday, October 29, 2013, 8.30 - 4.00 pm
About candidate drug GLPG0634
GLPG0634 is an orally-available, novel Janus kinase (JAK) inhibitor with
selectivity for JAK1 developed by Galapagos. JAKs are critical components of
signalling mechanisms utilized by a number of cytokines and growth factors,
including those that are elevated in rheumatoid arthritis patients. JAK
inhibitors have shown long-term efficacy in rheumatoid arthritis studies with an
early onset of action. GLPG0634 differentiates from other JAK inhibitors in
development by specifically targeting JAK1, a strategy which could result in a
better efficacy and safety profile. GLPG0634 is a fully proprietary program.
Upon successful completion of the Phase 2b studies in RA, AbbVie will license
the program and will assume sole responsibility for Phase 3 clinical development
and global manufacturing. GLPG0634 is also being developed for Crohn's disease.
About Galapagos
Galapagos (Euronext: GLPG; OTC: GLPYY) is specialized in novel modes-of-action,
with a large pipeline of five Phase 2 (two led by GSK), one Phase 1, six pre-
clinical, and 20 discovery small-molecule and antibody programs in cystic
fibrosis, inflammation, antibiotics, metabolic disease, and other indications.
AbbVie and Galapagos signed an agreement in CF where they work collaboratively
to develop and commercialize oral drugs that address two mutations in the CFTR
gene, the G551D and F508del mutation. In the field of inflammation, AbbVie and
Galapagos signed a worldwide license agreement whereby AbbVie will be
responsible for further development and commercialization of GLPG0634 after
Phase 2B. GLPG0634 is an orally-available, selective inhibitor of JAK1 for the
treatment of rheumatoid arthritis and potentially other inflammatory diseases,
currently in Phase 2B studies in RA and about to enter Phase 2 studies in
Crohn's disease. Galapagos has another selective JAK1 inhibitor in Phase 2 in
lupus and psoriasis, GSK2586184 (formerly GLPG0778, in-licensed by
GlaxoSmithKline in 2012). GLPG0974 is the first inhibitor of FFA2 to be
evaluated clinically for the treatment of IBD; this program is currently in a
Proof-of-Concept Phase 2 study. GLPG1205 is a first-in-class molecule that
targets inflammatory disorders and is currently in a First-in-Human Phase 1
study.
The Galapagos Group, including fee-for-service companies BioFocus, Argenta and
Fidelta, has around 800 employees and operates facilities in five countries,
with global headquarters in Mechelen, Belgium. Further information at:
www.glpg.com
Contact
Elizabeth Goodwin, Director Investor Relations
Tel: +31 6 2291 6240
ir@glpg.com
Galapagos forward-looking statements
This release may contain forward-looking statements, including, without
limitation, statements containing the words "believes," "anticipates,"
"expects," "intends," "plans," "seeks," "estimates," "may," "will," "could,"
"stands to," and "continues," as well as similar expressions. Such forward-
looking statements may involve known and unknown risks, uncertainties and other
factors which might cause the actual results, financial condition, performance
or achievements of Galapagos, or industry results, to be materially different
from any historic or future results, financial conditions, performance or
achievements expressed or implied by such forward-looking statements. Given
these uncertainties, the reader is advised not to place any undue reliance on
such forward-looking statements. These forward-looking statements speak only as
of the date of publication of this document. Galapagos expressly disclaims any
obligation to update any such forward-looking statements in this document to
reflect any change in its expectations with regard thereto or any change in
events, conditions or circumstances on which any such statement is based, unless
required by law or regulation.
Galapagos to present GLPG0634 at ACR: http://hugin.info/133350/R/1735889/581694.pdf
[HUG#1735889]
Grafico Azioni Galapagos NV (PK) (USOTC:GLPGF)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Galapagos NV (PK) (USOTC:GLPGF)
Storico
Da Giu 2023 a Giu 2024